In conclusion, we confirmed that SETD2-H3K36me3-FECH significantly potentiates the cytotoxic effect of erastin, thus providing new targets for ferroptosis intervention in ccRCC. The gene discussed is SETD2; the disease is nonpapillary renal cell carcinoma.